Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Arch Womens Ment Health ; 22(1): 129-132, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-29654412

RESUMO

CRP has been positively correlated with depressive symptomatology but this has received less study in postpartum depression (PPD). In this secondary analysis of a trial of PPD treatment, depressive symptoms (Structured Interview Guide for the Hamilton Depression Rating Scale-Atypical Depression Symptoms (SIGH-ADS29)) and serum CRP levels were assessed and associations between CRP and SIGH-ADS29 scores evaluated. The associations between baseline log CRP and depression response and remission were also assessed. Of the 35 women included, neither baseline log CRP nor exit log CRP was significantly associated with SIGH-ADS29 score. Baseline CRP was not associated with response or remission. In this sample of women with PPD, CRP was not associated with depressive symptoms nor response to treatment.


Assuntos
Proteína C-Reativa/metabolismo , Depressão Pós-Parto/sangue , Transtorno Depressivo Maior/sangue , Adulto , Índice de Massa Corporal , Depressão Pós-Parto/diagnóstico , Feminino , Humanos
2.
Bipolar Disord ; 19(4): 295-304, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28665044

RESUMO

OBJECTIVE: We conducted a prospective naturalistic study of pregnant women with bipolar disorder (BD) to evaluate symptoms of BD across childbearing and assess whether pharmacotherapy reduced their severity. METHODS: Assessments were scheduled at 20, 30, and 36 weeks' gestation and 2, 12, 26, and 52 weeks postpartum. Symptoms were assessed using the Structured Interview Guide for the Hamilton Depression Rating Scale-Atypical Depression Supplement (SIGH-ADS) and Mania Rating Scale (MRS). RESULTS: Pregnant women (N=152) with BD were evaluated; 88 women (58%) were treated and 64 untreated (42%) with psychotropic drugs during pregnancy. Among the 88 women treated, 23 (26%) discontinued their medication in the first trimester and the remaining 65 (74%) were exposed throughout pregnancy or in the second and third trimesters. More than two-thirds (73%) of the women who remained in the study took psychotropic agents postpartum. The mean scores on the SIGH-ADS were in the mild range of depressive symptoms in both the psychotropic-treated and untreated groups in both pregnancy and postpartum. The majority of women had no or few symptoms of mania. Of the pregnant women treated with psychotropic agents, 66% received a guideline-concordant drug, and 34% received either antidepressant monotherapy (for BD I) or mono- or polypharmacy with a variety of other agents. CONCLUSIONS: This sample of perinatal women with BD was characterized by mild residual symptoms of depression independent of pharmacotherapy, which poses a risk for recurrence and impaired parenting. The treatment of childbearing women with BD deserves urgent clinical and research attention to improve psychiatric outcomes.


Assuntos
Transtorno Bipolar , Período Pós-Parto/psicologia , Complicações na Gravidez , Gestantes/psicologia , Psicotrópicos/uso terapêutico , Transtornos Puerperais , Adulto , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Feminino , Idade Gestacional , Humanos , Conduta do Tratamento Medicamentoso , Avaliação de Processos e Resultados em Cuidados de Saúde , Assistência Perinatal/métodos , Assistência Perinatal/estatística & dados numéricos , Gravidez , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/tratamento farmacológico , Complicações na Gravidez/psicologia , Estudos Prospectivos , Escalas de Graduação Psiquiátrica , Transtornos Puerperais/diagnóstico , Transtornos Puerperais/tratamento farmacológico , Transtornos Puerperais/psicologia , Prevenção Secundária/métodos , Estados Unidos
3.
Arch Womens Ment Health ; 19(2): 409-13, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25956588

RESUMO

We examined estradiol (E2) and estrone (E1) concentrations in breastfeeding mother-infant dyads. The mothers had postpartum depression and were participants in a randomized clinical trial with three treatments (transdermal E2, sertraline, and placebo). Neither infant E1 and E2 concentrations nor infant growth differed across the treatments. Transdermal E2 administration of 50 to 200 mcg/day for breastfeeding women did not affect infant E1 or E2 concentrations or infant growth.


Assuntos
Aleitamento Materno , Depressão Pós-Parto/tratamento farmacológico , Estradiol/sangue , Estrona/administração & dosagem , Sertralina/administração & dosagem , Administração Cutânea , Adulto , Depressão Pós-Parto/diagnóstico , Depressão Pós-Parto/psicologia , Estradiol/administração & dosagem , Feminino , Humanos , Recém-Nascido , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Adulto Jovem
4.
Arch Womens Ment Health ; 18(2): 139-146, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25589155

RESUMO

We examined the risk-benefit profile of sertraline treatment during breastfeeding, summarized the available literature on sertraline use, presented previously unpublished data, and performed a correlation-based meta-analysis of sertraline serum levels in mother-infant pairs. We conducted a search of PubMed and the National Library of Medicine LactMed database. We performed a meta-analysis to examine correlations between maternal and infant serum sertraline levels in the existing literature and in previously unpublished data. Of 167 available infant sertraline levels, 146 (87.4 %) were below the limit of detection, and the meta-analysis found no significant relationship between maternal and infant sertraline concentrations. Of 150 infant desmethylsertraline levels, 105 (70.0 %) were below the limit of detection. The correlation analysis revealed a significant relationship between maternal and infant desmethylsertraline concentrations, but this metabolite has only a fraction of the activity of sertraline. A significant relationship was also found for the sum of sertraline and desmethylsertraline, which stems primarily from the contribution of desmethylsertraline. Sertraline is a first-line drug for breastfeeding women due to documented low levels of exposure in breastfeeding infants and very few adverse events described in case reports. Based on the current literature, neither routine serum sampling nor genotyping is warranted for breastfeeding mothers taking sertraline and/or their infants. Routine pediatric care is appropriate monitoring for breastfed infants of women who take sertraline monotherapy.


Assuntos
Antidepressivos/uso terapêutico , Aleitamento Materno , Transtorno Depressivo/tratamento farmacológico , Leite Humano/química , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Sertralina/uso terapêutico , Antidepressivos/sangue , Transtorno Depressivo/sangue , Transtorno Depressivo/metabolismo , Feminino , Humanos , Lactente , Lactação , Leite Humano/metabolismo , Inibidores Seletivos de Recaptação de Serotonina/sangue , Sertralina/sangue
5.
Sci Rep ; 14(1): 7123, 2024 03 26.
Artigo em Inglês | MEDLINE | ID: mdl-38532120

RESUMO

Nilotinib is a highly effective treatment for chronic myeloid leukemia but has been consistently associated with the development of nilotinib-induced arterial disease (NAD) in a subset of patients. To date, which cell types mediate this effect and whether NAD results from on-target mechanisms is unknown. We utilized human induced pluripotent stem cells (hiPSCs) to generate endothelial cells and vascular smooth muscle cells for in vitro study of NAD. We found that nilotinib adversely affects endothelial proliferation and migration, in addition to increasing intracellular nitric oxide. Nilotinib did not alter endothelial barrier function or lipid uptake. No effect of nilotinib was observed in vascular smooth muscle cells, suggesting that NAD is primarily mediated through endothelial cells. To evaluate whether NAD results from enhanced inhibition of ABL1, we generated multiple ABL1 knockout lines. The effects of nilotinib remained unchanged in the absence of ABL1, suggesting that NAD results from off- rather than on-target signaling. The model established in the present study can be applied to future mechanistic and patient-specific pharmacogenomic studies.


Assuntos
Células-Tronco Pluripotentes Induzidas , Doenças Vasculares , Humanos , Células Endoteliais , NAD , Inibidores de Proteínas Quinases/farmacologia , Pirimidinas/farmacologia , Doenças Vasculares/tratamento farmacológico
7.
Stem Cell Reports ; 18(6): 1371-1387, 2023 06 13.
Artigo em Inglês | MEDLINE | ID: mdl-37315525

RESUMO

The nutritional requirements for human induced pluripotent stem cell (hiPSC) growth have not been extensively studied. Here, building on our prior work that established the suitable non-basal medium components for hiPSC growth, we develop a simplified basal medium consisting of just 39 components, demonstrating that many ingredients of DMEM/F12 are either not essential or are at suboptimal concentrations. This new basal medium along with the supplement, which we call BMEM, enhances the growth rate of hiPSCs over DMEM/F12-based media, supports derivation of multiple hiPSC lines, and allows differentiation to multiple lineages. hiPSCs cultured in BMEM consistently have enhanced expression of undifferentiated cell markers such as POU5F1 and NANOG, along with increased expression of markers of the primed state and reduced expression of markers of the naive state. This work describes titration of the nutritional requirements of human pluripotent cell culture and identifies that suitable nutrition enhances the pluripotent state.


Assuntos
Células-Tronco Pluripotentes Induzidas , Humanos , Necessidades Nutricionais , Técnicas de Cultura de Células , Diferenciação Celular , Suplementos Nutricionais
8.
Semin Perinatol ; 44(3): 151221, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32115202

RESUMO

Pharmacologic interventions play a major role in obstetrical care throughout pregnancy, labor and delivery and the postpartum. Traditionally, obstetrical providers have utilized standard dosing regimens developed for non-obstetrical indications based on pharmacokinetic knowledge from studies in men or non-pregnant women. With the recognition of pregnancy as a special pharmacokinetic population in the late 1990s, investigators have begun to study drug disposition in this unique patient dyad. Many of the basic physiologic changes that occur during pregnancy have significant impact on drug absorption, distribution and clearance. Activity of Phase I and Phase II drug metabolizing enzymes are differentially altered by pregnancy, resulting in drug concentrations sufficiently different for some medications that efficacy or toxicity is affected. Placental transporters play a major dynamic role in determining fetal drug exposure. In the past two decades, we have begun to expand our understanding of obstetrical pharmacology; however, to truly optimize pharmacologic care of our pregnant patients and their developing fetus, additional research is critically needed.


Assuntos
Absorção Fisiológica/fisiologia , Vias de Eliminação de Fármacos/fisiologia , Troca Materno-Fetal/fisiologia , Farmacocinética , Placenta/metabolismo , Gravidez/fisiologia , Distribuição Tecidual/fisiologia , Transportadores de Cassetes de Ligação de ATP/metabolismo , Débito Cardíaco/fisiologia , Sistema Enzimático do Citocromo P-450/metabolismo , Feminino , Taxa de Filtração Glomerular/fisiologia , Humanos , Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo , Proteínas de Transporte de Cátions Orgânicos/metabolismo , Preparações Farmacêuticas/metabolismo , Volume Plasmático/fisiologia , Gravidez/metabolismo
9.
J Cardiovasc Transl Res ; 13(3): 377-389, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32078739

RESUMO

Chemotherapy-induced cardiovascular toxicity (CICT) is a well-established risk for cancer survivors and causes diseases such as heart failure, arrhythmia, vascular dysfunction, and atherosclerosis. As our knowledge of the precise cardiovascular risks of each chemotherapy agent has improved, it has become clear that genomics is one of the most influential predictors of which patients will experience cardiovascular toxicity. Most recently, GWAS-led, top-down approaches have identified novel genetic variants and their related genes that are statistically related to CICT. Importantly, the advent of human-induced pluripotent stem cell (hiPSC) models provides a system to experimentally test the effect of these genomic findings in vitro, query the underlying mechanisms, and develop novel strategies to mitigate the cardiovascular toxicity liabilities due to these mechanisms. Here we review the cardiovascular toxicities of chemotherapy drugs, discuss how these can be modeled in vitro, and suggest how these models can be used to validate genetic variants that predispose patients to these effects.


Assuntos
Antineoplásicos/toxicidade , Doenças Cardiovasculares/genética , Variação Genética , Genômica , Células-Tronco Pluripotentes Induzidas/efeitos dos fármacos , Animais , Cardiotoxicidade , Doenças Cardiovasculares/induzido quimicamente , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/fisiopatologia , Células Cultivadas , Predisposição Genética para Doença , Ensaios de Triagem em Larga Escala , Humanos , Células-Tronco Pluripotentes Induzidas/metabolismo , Células-Tronco Pluripotentes Induzidas/patologia , Mutação , Variantes Farmacogenômicos , Fenótipo , Polimorfismo de Nucleotídeo Único , Medição de Risco , Fatores de Risco
10.
Stem Cell Reports ; 14(2): 256-270, 2020 02 11.
Artigo em Inglês | MEDLINE | ID: mdl-31928950

RESUMO

Human induced pluripotent stem cell (hiPSC) culture has become routine, yet the cost of pluripotent cell media, frequent medium changes, and the reproducibility of differentiation have remained restrictive. Here, we describe the formulation of a hiPSC culture medium (B8) as a result of the exhaustive optimization of medium constituents and concentrations, establishing the necessity and relative contributions of each component to the pluripotent state and cell proliferation. The reagents in B8 represent only 3% of the costs of commercial media, made possible primarily by the in-lab generation of three E. coli-expressed, codon-optimized recombinant proteins: fibroblast growth factor 2, transforming growth factor ß3, and neuregulin 1. We demonstrate the derivation and culture of 34 hiPSC lines in B8 as well as the maintenance of pluripotency long term (over 100 passages). This formula also allows a weekend-free feeding schedule without sacrificing capacity for differentiation.


Assuntos
Técnicas de Cultura de Células/economia , Técnicas de Cultura de Células/métodos , Células-Tronco Pluripotentes Induzidas/citologia , Bioensaio , Diferenciação Celular , Proliferação de Células , Células Cultivadas , Humanos
11.
Cardiovasc Res ; 115(5): 935-948, 2019 04 15.
Artigo em Inglês | MEDLINE | ID: mdl-30689737

RESUMO

The genomic predisposition to oncology-drug-induced cardiovascular toxicity has been postulated for many decades. Only recently has it become possible to experimentally validate this hypothesis via the use of patient-specific human-induced pluripotent stem cells (hiPSCs) and suitably powered genome-wide association studies (GWAS). Identifying the individual single nucleotide polymorphisms (SNPs) responsible for the susceptibility to toxicity from a specific drug is a daunting task as this precludes the use of one of the most powerful tools in genomics: comparing phenotypes to close relatives, as these are highly unlikely to have been treated with the same drug. Great strides have been made through the use of candidate gene association studies (CGAS) and increasingly large GWAS studies, as well as in vivo whole-organism studies to further our mechanistic understanding of this toxicity. The hiPSC model is a powerful technology to build on this work and identify and validate causal variants in mechanistic pathways through directed genomic editing such as CRISPR. The causative variants identified through these studies can then be implemented clinically to identify those likely to experience cardiovascular toxicity and guide treatment options. Additionally, targets identified through hiPSC studies can inform future drug development. Through careful phenotypic characterization, identification of genomic variants that contribute to gene function and expression, and genomic editing to verify mechanistic pathways, hiPSC technology is a critical tool for drug discovery and the realization of precision medicine in cardio-oncology.


Assuntos
Antineoplásicos/efeitos adversos , Cardiopatias/induzido quimicamente , Células-Tronco Pluripotentes Induzidas/efeitos dos fármacos , Variantes Farmacogenômicos , Polimorfismo de Nucleotídeo Único , Cardiotoxicidade , Células Cultivadas , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla , Cardiopatias/genética , Cardiopatias/metabolismo , Cardiopatias/patologia , Humanos , Células-Tronco Pluripotentes Induzidas/metabolismo , Células-Tronco Pluripotentes Induzidas/patologia , Fenótipo , Locos de Características Quantitativas , Medição de Risco , Fatores de Risco
12.
J Affect Disord ; 243: 220-225, 2019 01 15.
Artigo em Inglês | MEDLINE | ID: mdl-30248632

RESUMO

OBJECTIVE: The hypotheses were: (1) pregnant women with bipolar disorder (BD) have less favorable pregnancy outcomes than unaffected women, and (2) psychotropic treated women with BD have better outcomes than un-medicated women. METHOD: This prospective study included 174 mother-infant dyads. Women had BD without psychotropic exposure (BD-NP, n = 38), BD with psychotropic treatment (BD-P, n = 49), or neither psychotropic exposure nor major mood disorder (Comp, n = 87). Maternal characteristics were completed at 20 weeks gestation and evaluated for associations with delivery and birth outcomes. We performed multiple regressions on infant outcomes with adjustment for maternal age, race, employment status, use of illicit drugs and pre-pregnancy BMI. RESULTS: The BP-P, BP-NP and Comp groups varied significantly on sociodemographic characteristics. Women with BD were more likely to be less educated, unemployed, single, and use tobacco and illicit drugs than women in the Comp group. Compared to women with BD-NP, women with BD-P were more likely to be older and educated. Approximately 10% of all infants were delivered preterm. No significant differences in outcome occurred for APGAR scores < 8, NICU admissions, sex or infant length. Infants of mothers with BD-NP had significantly smaller head circumferences (HC) than the other groups, adjustment for confounding variables mitigated this association. CONCLUSIONS: The overall pregnancy outcomes for women with BD were similar to those in the Comp group. The reduced HC in women with untreated BD appears due to factors related to disadvantaged sociodemographic status, a higher proportion of female births, and/or a protective effect of medication in the BD-P group.


Assuntos
Transtorno Bipolar/tratamento farmacológico , Complicações na Gravidez/induzido quimicamente , Complicações na Gravidez/epidemiologia , Resultado da Gravidez/epidemiologia , Psicotrópicos/efeitos adversos , Adolescente , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pennsylvania/epidemiologia , Gravidez , Nascimento Prematuro/epidemiologia , Estudos Prospectivos , Psicotrópicos/uso terapêutico , Fatores Socioeconômicos , Adulto Jovem
13.
J Affect Disord ; 246: 69-73, 2019 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-30578948

RESUMO

BACKGROUND: The aim of this study was to investigate the validity of the WHIPLASHED clinician-administered interview, a mnemonic of questions on clinical factors and illness course used to screen for bipolar disorder, as a self-report questionnaire. METHODS: Participants (n = 82) were females recruited from an outpatient academic women's mental health clinic. Relevant symptom data were extracted from a self-report questionnaire designed to parallel the WHIPLASHED interview questions. A score of ≥5 on WHIPLASHED was defined as a positive screen for bipolar spectrum disorder by its developer. We examined the capacity of self-reported WHIPLASHED scores ≥5 to differentiate bipolar from unipolar depression in women. Diagnostic assessments were conducted with the Mini International Neuropsychiatric Interview. RESULTS: Women were diagnosed with unipolar (n = 54) and bipolar (n = 28) depression. The majority of subjects were white (67%), employed (68%) and married (57%) with a mean age of 36.8 years. The receiver operating characteristic curve demonstrated that WHIPLASHED had strong predictive ability (AUC = 0.877) in differentiating bipolar from unipolar depression. A cutoff score of ≥5 generated 96% sensitivity and 52% specificity, while raising the threshold to 6 generated 89% sensitivity and 76% specificity for a bipolar disorder diagnosis. LIMITATIONS: Our sample was small and composed of female patients at a single treatment center. CONCLUSIONS: In this sample, WHIPLASHED was a valid screening tool to differentiate bipolar from unipolar depression. While existing instruments focus on primary symptoms of bipolar disorder, the WHIPLASHED is useful in exploring subtypes of bipolar disorder in which depression dominates the clinical course.


Assuntos
Transtorno Bipolar/diagnóstico , Transtorno Depressivo Maior/diagnóstico , Programas de Rastreamento/métodos , Escalas de Graduação Psiquiátrica/estatística & dados numéricos , Adulto , Transtorno Bipolar/psicologia , Transtorno Depressivo Maior/psicologia , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , Curva ROC , Autorrelato , Sensibilidade e Especificidade , Inquéritos e Questionários
14.
J Clin Psychiatry ; 78(5): 605-611, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28570796

RESUMO

OBJECTIVE: To determine whether infants exposed in utero to serotonin reuptake inhibitor (SRI) antidepressants or a DSM-IV-TR-defined mood disorder have significantly more neonatal discontinuation signs compared to an unexposed group of infants at 2-4 weeks after birth. METHODS: This secondary analysis was derived from 2 observational studies with enrollment from July 2000 to December 2011 in Cleveland, Ohio, and Pittsburgh, Pennsylvania. Mothers (n = 214) belonged to one of 3 groups based on exposure status during pregnancy: (1) Comparison-women who did not take psychotropics during pregnancy and had no major mood disorder; (2) SRI-exposed-women with a mood disorder who were taking an SRI but no benzodiazepines; and (3) Mood Disorder-women with depression or bipolar disorder who did not take psychotropic medications. The infants were examined for signs according to the Finnegan Scale by evaluators blind to maternal exposure status. RESULTS: The rates of sign presence (defined as a score ≥ 2 on the Finnegan Scale) in the SRI, Mood Disorder, and Comparison groups were similar at 34.1%, 35.1%, and 30.4%, respectively. Women in the SRI group had a significantly higher preterm birth rate (24.4%) compared to the other 2 groups (7.4% and 8.9% in the Mood Disorder and Comparison groups, respectively; P = .012). Preterm newborns had a significantly higher sign rate compared to full-term newborns (54% vs 31%, P = .020). We observed a significant relationship between Finnegan signs and preterm birth. CONCLUSIONS: The presence of neonatal signs at 2-4 weeks was more closely associated with prematurity than with in utero SRI or mood disorder exposure. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00279370 and NCT00585702.


Assuntos
Antidepressivos/efeitos adversos , Antimaníacos/efeitos adversos , Transtorno Bipolar/tratamento farmacológico , Transtorno Depressivo Maior/tratamento farmacológico , Síndrome de Abstinência Neonatal/etiologia , Complicações na Gravidez/tratamento farmacológico , Efeitos Tardios da Exposição Pré-Natal/diagnóstico , Efeitos Tardios da Exposição Pré-Natal/etiologia , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Adulto , Antidepressivos/uso terapêutico , Antimaníacos/uso terapêutico , Feminino , Humanos , Recém-Nascido , Doenças do Prematuro/induzido quimicamente , Doenças do Prematuro/diagnóstico , Síndrome de Abstinência Neonatal/diagnóstico , Gravidez , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico
15.
J Psychiatr Res ; 73: 79-85, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26692255

RESUMO

As serotonin reuptake inhibitor (SRI) use may decrease platelet function, previous research has shown a relationship between SRI use and an increased risk for bruising and bleeding. The literature regarding the association between SRI use during pregnancy and increased bleeding at delivery, referred to as postpartum hemorrhage (PPH), is mixed. In secondary analyses from two prospective observational studies of pregnant women with mood disorders, 263 women were exposed to an SRI (n = 51) or not (n = 212) in the third trimester. To be precise, we used the terminology estimated blood loss (EBL) >600 cc rather than the term PPH because the current definition of PPH differs. The occurrence of EBL >600 cc was determined using the Peripartum Events Scale (PES) completed from obstetrical records by a blinded medically trained member of the study team. EBL >600 cc occurred in 8.7% of women in this cohort. There was no statistically significant difference in the rates of EBL >600 cc in the 24 h after delivery in women taking SRIs during the third trimester (9.8%) compared to non-exposed women (8.5%). Utilizing generalizing estimating equations, the odds of EBL >600 cc in each group were not significantly different (OR 1.17, CI-0.41-3.32, p = 0.77). When the SRI group was limited to women with exposure at the time of delivery, the difference in the odds of EBL >600 cc was unchanged (OR 1.16, CI = 0.37-3.64, p = 0.79). In population, both third trimester and use at delivery of SRIs during pregnancy was not associated with an increased risk of excessive blood loss.


Assuntos
Hemorragia Pós-Parto/induzido quimicamente , Terceiro Trimestre da Gravidez/efeitos dos fármacos , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Adolescente , Adulto , Depressão/tratamento farmacológico , Feminino , Humanos , Hemorragia Pós-Parto/epidemiologia , Gravidez , Escalas de Graduação Psiquiátrica , Estudos Retrospectivos , Método Simples-Cego , Estatísticas não Paramétricas , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA